Press Releases

Investors

Press Releases

Date Title and Summary Additional Formats
Toggle Summary Takeda and Arrowhead Collaborate to Co-Develop and Co-Commercialize ARO-AAT for Alpha-1 Antitrypsin-Associated Liver Disease
−        Potential first-in-class therapy designed to treat the underlying cause of liver disease associated with AATD −        Arrowhead is eligible to receive up to $1.04B including an upfront payment of $300M and potential development, regulatory and commercial milestones up to $740M −       
View HTML
Toggle Summary Arrowhead Pharmaceuticals to Participate in Upcoming Investor Conference
PASADENA, Calif.--( BUSINESS WIRE )--Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced that it is scheduled to participate in the following upcoming event: Chardan Virtual 4th Annual Genetic Medicines Conference October 6, 2020, 1:30 p.m. EDT – Vince Anzalone, CFA, Arrowhead’s vice
View HTML
Toggle Summary Arrowhead Pharmaceuticals Reports Inducement Grants under NASDAQ Marketplace Rule 5635(c)(4)
PASADENA, Calif. --(BUSINESS WIRE)--Sep. 24, 2020-- Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that as an inducement to entering into employment with the Company, on September 11, 2020 , the Compensation Committee of the Board of Directors approved “inducement” grants to 30 new
View HTML
Toggle Summary Arrowhead ARO-AAT Phase 2 Interim Results in Patients with Alpha-1 Liver Disease Demonstrate Improvements in Key Parameters after Six Months of Treatment
- Up to 97% reduction in intra-hepatic Z-AAT polymer - Up to 95% reduction in intra-hepatic total Z-AAT burden - Up to 66% and 58% reduction in circulating ALT and GGT levels respectively - Up to 26% improvement in FibroScan values PASADENA, Calif. --(BUSINESS WIRE)--Sep.
View HTML
Toggle Summary Arrowhead Pharmaceuticals to Participate in Upcoming September 2020 Conferences
PASADENA, Calif. --(BUSINESS WIRE)--Sep. 8, 2020-- Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced that it is scheduled to participate in the following upcoming events: Citi’s 15th Annual BioPharma Virtual Conference September 9, 2020 – Arrowhead management will participate in
View HTML
Toggle Summary Arrowhead Pharmaceuticals Appoints Oye Olukotun to Board of Directors
PASADENA, Calif. --(BUSINESS WIRE)--Sep. 8, 2020-- Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced that the board of directors appointed veteran pharmaceutical industry executive Oye Olukotun , M.D., MPH, as an independent director of the company, with a term beginning effective
View HTML
Toggle Summary Arrowhead Presents Positive New Phase 1/2 Clinical Data on Cardiometabolic Candidates ARO-APOC3 and ARO-ANG3 at European Society of Cardiology Congress 2020
PASADENA, Calif. --(BUSINESS WIRE)--Aug. 31, 2020-- Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced the presentation of positive new Phase 1/2 clinical data on two RNAi-based cardiometabolic candidates, ARO-APOC3 targeting apolipoprotein C-III (APOC3) being developed as a treatment
View HTML
Toggle Summary Arrowhead and Collaborator Janssen Present Phase 2 Clinical Data on Investigational Hepatitis B Therapeutic JNJ-3989 at The Digital Liver Congress
PASADENA, Calif. --(BUSINESS WIRE)--Aug. 28, 2020-- Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced the presentation of Phase 2 clinical data from the AROHBV1001 phase 1/2 study on a double combination of JNJ-3989 (formerly ARO-HBV) and a nucleos(t)ide analog (NA) with collaborator
View HTML
Toggle Summary Arrowhead Pharmaceuticals to Participate in Upcoming August 2020 Conferences
PASADENA, Calif. --(BUSINESS WIRE)--Aug. 18, 2020-- Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced that it is scheduled to participate in the following upcoming events: The Digital International Liver Congress - The Annual Meeting of the European Association for the Study of the
View HTML
Toggle Summary Arrowhead Pharmaceuticals Initiates Phase 1b Study of ARO-HIF2 for Treatment of Clear Cell Renal Cell Carcinoma
PASADENA, Calif. --(BUSINESS WIRE)--Aug. 18, 2020-- Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced that it has dosed the first patient in AROHIF21001, a Phase 1b dose-finding clinical study of ARO-HIF2, the company’s investigational RNA interference (RNAi) therapeutic being developed
View HTML